17 results match your criteria: "Jimenez Diaz Foundation Hospital[Affiliation]"
Int Clin Psychopharmacol
January 2025
Department of Psychiatry, Jimenez Diaz Foundation Hospital.
Arch Esp Urol
May 2023
Department of Urology, Jiménez Díaz Foundation Hospital, 28040 Madrid, Spain.
Minerva Urol Nephrol
April 2023
Department of Endoscopy-Endourology, Jesús Usón Minimally Invasive Surgery Center Foundation, Cáceres, Spain.
Background: A major limitation in the treatment of upper urinary tract urothelial carcinoma is the limited use of adjuvant therapy due to the drawbacks of current techniques for intracavitary instillation. The aim was to assess, in a large animal model, a biodegradable ureteral stent coated with silk fibroin for mitomycin release, i.e.
View Article and Find Full Text PDFPsychiatry Res Case Rep
June 2022
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.
N/A.
View Article and Find Full Text PDFAm J Clin Nutr
December 2022
Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.
Background: Choline and betaine intakes have been related to cardiovascular health.
Objectives: We aimed to explore the relation between 1-y changes in dietary intake of choline or betaine and 1-y changes in cardiometabolic and renal function traits within the frame of the PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial.
Methods: We used baseline and 1-y follow-up data from 5613 participants (48.
Int J Soc Psychiatry
March 2023
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.
We present the case of a 42-year-old female patient with a diagnosis of schizophrenia who, 24 hours after the onset of the Russian invasion of Ukraine, developed a delirium on this topic. This case report illustrates how current news is processed by psychotic patients. Relevant current events can be incorporated into delusional themes due to the intensity and immediacy of information by the media.
View Article and Find Full Text PDFBipolar Disord
February 2022
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.
Rev Psiquiatr Salud Ment (Engl Ed)
June 2021
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain; Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain; Department of Psychiatry, General Hospital of Villalba, Madrid, Spain; Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain; Department of Psychiatry, Centre Hospitalier Universitaire de Nîmes, France; Universidad Católica del Maule, Talca, Chile; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), Madrid, Spain. Electronic address:
Rev Psiquiatr Salud Ment (Engl Ed)
June 2021
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, España; Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, España; Department of Psychiatry, General Hospital of Villalba, Madrid, España; Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, España; Department of Psychiatry, Centre Hospitalier Universitaire de Nîmes, Francia; Universidad Católica del Maule, Talca, Chile; Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), Madrid, España. Electronic address:
Early Interv Psychiatry
December 2021
Early Intervention Service for Psychosis, Department of Mental Health, Parc Taulí Hospital Universitari, I3PT, Universitat Autònoma de Barcelona (Department of Psychiatry and Forensic Medicine), CIBERSAM, Sabadell, Spain.
Aims: Non-compliance is still an important problem in psychotic patients. Although antipsychotic (AP) treatment leads to a decrease in psychotic relapses, there are no clear recommendations about how long treatment should be maintained after first-episode psychosis (FEP) and no indication of the rates and causes of treatment withdrawal in this group.
Methods: We evaluated a large sample of patients with FEP for 2 years to compare the time to all-cause treatment discontinuation of AP drugs and the time to the first relapse.
Psychiatry Res
August 2020
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain; Department of Psychiatry, Madrid Autonomous University, Madrid, Spain; Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain; Department of Psychiatry, General Hospital of Villalba, Madrid, Spain; Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain; Universidad Católica del Maule, Talca, Chile; Department of Psychiatry. Centre Hospitalier Universitaire de Nîmes, Spain.
• The coronavirus disease 2019 (COVID-19), first reported on December 31, 2019 in China, has currently spread worldwide and became pandemic on March 11. • Besides causing an emotional impact in people affected, COVID-19 pandemic could specially affect people with previous mental health conditions, resulting in relapses or worsening of an already existing mental health condition because of high susceptibility to stress compared with the general population. • Worldwide, in different countries, among them Spain, it has been necessary to adopt confinement measures to preserve public health.
View Article and Find Full Text PDFSchizophr Res
August 2020
Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain; Department of Psychiatry, Madrid Autonomous University, Madrid, Spain. Electronic address:
Delusional topics tend to rapidly incorporate popular hot topical issues. Thus, the current coronavirus COVID-19 pandemic has rapidly reached delusional themes in patients with psychiatric disorders. Here we present the clinical case of a Spanish woman with bipolar disorder that included coronavirus infection in her delusional themes even faster than the real infection reached mainland Spain.
View Article and Find Full Text PDFJ Thorac Oncol
October 2019
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. Electronic address:
Introduction: This first-time-in-humans study assessed the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of GSK2879552 in patients with relapsed or refractory SCLC.
Methods: This phase I, multicenter, open-label study (NCT02034123) enrolled patients (≥18 years old) with relapsed or refractory SCLC (after ≥1 platinum-containing chemotherapy or refusal of standard therapy). Part 1 was a dose-escalation study; Part 2 was a dose-expansion study.